{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.previousAnswerVersion.answeringMemberPrinted=Dr+Th%C3%A9r%C3%A8se+Coffey&min-answer.dateOfAnswer=2017-11-17", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.previousAnswerVersion.answeringMemberPrinted=Dr+Th%C3%A9r%C3%A8se+Coffey&min-answer.dateOfAnswer=2017-11-17", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.previousAnswerVersion.answeringMemberPrinted=Dr+Th%C3%A9r%C3%A8se+Coffey&min-answer.dateOfAnswer=2017-11-17&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.previousAnswerVersion.answeringMemberPrinted=Dr+Th%C3%A9r%C3%A8se+Coffey&min-answer.dateOfAnswer=2017-11-17&_page=0", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.previousAnswerVersion.answeringMemberPrinted=Dr+Th%C3%A9r%C3%A8se+Coffey&min-answer.dateOfAnswer=2017-11-17", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.previousAnswerVersion.answeringMemberPrinted=Dr+Th%C3%A9r%C3%A8se+Coffey&min-answer.dateOfAnswer=2017-11-17", "items" : [{"_about" : "http://data.parliament.uk/resources/1504776", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504776/answer", "answerText" : {"_value" : "<p>The information requested is not yet held in the format requested as the accounts for 2021/22 are currently being audited.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504776/answer/previousversion/17726", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-20T14:35:04.54Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Temporary Employment"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the total cost to NHS hospitals was of using (a) agency and (b) bank staff in each region in England in the 2021-22 financial year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4822", "label" : {"_value" : "Biography information for Feryal Clark"}
      }
      , "tablingMemberConstituency" : {"_value" : "Enfield North"}
      , "tablingMemberPrinted" : [{"_value" : "Feryal Clark"}
      ], "uin" : "47698"}
    , {"_about" : "http://data.parliament.uk/resources/1504790", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504790/answer", "answerText" : {"_value" : "<p>For patients whose immune system means they are at the highest risk from COVID-19 and who test positive for the virus, treatments can be accessed directly through COVID Medicine Delivery Units (CMDUs). Those patients at high risk of COVID-19 who are ineligible to access treatments via CMDUs can access antivirals via the PANORAMIC national study.<\/p><p>The Department and NHS England are monitoring the uptake of antiviral treatment against those digitally identified as eligible. In England, 95% of eligible non-hospitalised patients who have received an antiviral treatment to date were treated within five days from the date of symptom onset.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504790/answer/previousversion/17717", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-27T15:24:35.023Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the level of access to antiviral treatments for people who are acutely vulnerable to covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
      }
      , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
      ], "uin" : "47395"}
    , {"_about" : "http://data.parliament.uk/resources/1504791", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504791/answer", "answerText" : {"_value" : "<p>The UK Health Security Agency (UKHSA) procured over 150,000 doses of Monkeypox vaccines, with 70,000 vials arriving in the United Kingdom by September and a further 80,000 vials in October.<\/p><p> <\/p><p>The UKHSA has endorsed the use of \u2018fractional dosing\u2019, in which people aged 18 years old and over can be offered a 0.1 millilitre dose of the Jynneos smallpox vaccine, replacing the 0.5 millilitre dose typically administered. This will enable up to a five-fold increase in the number of people offered vaccination with the same level of effectiveness.\u202f There has been no pause in the programme since it began.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4679", "label" : {"_value" : "Biography information for Neil O'Brien"}
        }
        , "answeringMemberConstituency" : {"_value" : "Harborough"}
        , "answeringMemberPrinted" : {"_value" : "Neil O'Brien"}
        , "dateOfAnswer" : {"_value" : "2022-10-31", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504791/answer/previousversion/17718", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-10-31T17:40:50.987Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Monkeypox: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to accelerate resumption of the Monkeypox vaccination rollout.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
      }
      , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
      ], "uin" : "47396"}
    , {"_about" : "http://data.parliament.uk/resources/1504818", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504818/answer", "answerText" : {"_value" : "<p>RAPID C-19 has enabled active multi-agency oversight of national and international trial evidence for COVID-19 therapies for potential treatment and prophylactic indications. To date, evidence has strongly supported treatment use, although emerging evidence on prophylactic use is continuing to be reviewed.<\/p><p>We are monitoring a range of treatment products through the Protect-V study, including sotrovimab and niclosamide, as administered over a six-month period in vulnerable renal and immunosuppressed patients, to assess their effectiveness and suitability. Where material evidence is identified, the formation and implementation of United Kingdom-wide clinical access policies will follow as previously for other treatments.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504818/answer/previousversion/17719", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-27T15:27:13.937Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help evaluate future effectiveness of prophylactic covid-19 treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
      }
      , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
      ], "uin" : "47397"}
    , {"_about" : "http://data.parliament.uk/resources/1504891", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504891/answer", "answerText" : {"_value" : "<p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England\u2019s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4592", "label" : {"_value" : "Biography information for Dr Caroline Johnson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Sleaford and North Hykeham"}
        , "answeringMemberPrinted" : {"_value" : "Dr Caroline Johnson"}
        , "dateOfAnswer" : {"_value" : "2022-09-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "47663"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504891/answer/previousversion/17723", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-20T14:29:09.243Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Respiratory Syncytial Virus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, on what date he expects NHS England\u2019s Palivizumab Expert Group to respond to the request from the JCVI to consider the eligibility of children with spinal muscular atrophy to receive the Palivizumab vaccination against respiratory syncytial virus.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4769", "label" : {"_value" : "Biography information for Daisy Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "St Albans"}
      , "tablingMemberPrinted" : [{"_value" : "Daisy Cooper"}
      ], "uin" : "47662"}
    , {"_about" : "http://data.parliament.uk/resources/1504892", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504892/answer", "answerText" : {"_value" : "<p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England\u2019s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4592", "label" : {"_value" : "Biography information for Dr Caroline Johnson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Sleaford and North Hykeham"}
        , "answeringMemberPrinted" : {"_value" : "Dr Caroline Johnson"}
        , "dateOfAnswer" : {"_value" : "2022-09-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "47662"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504892/answer/previousversion/17724", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-20T14:29:09.29Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Respiratory Syncytial Virus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to recommendations in the consensus statement of the 2017 International Conference on the Standards of Care on the use of Palivizumab for some categories of children with spinal muscular atrophy to protect from respiratory syncytial virus, if he will take steps to urgently review the eligibility criteria for the Palivizumab vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4769", "label" : {"_value" : "Biography information for Daisy Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "St Albans"}
      , "tablingMemberPrinted" : [{"_value" : "Daisy Cooper"}
      ], "uin" : "47663"}
    , {"_about" : "http://data.parliament.uk/resources/1504900", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504900/answer", "answerText" : {"_value" : "<p>Under the Care Act 2014, local authorities have a duty to manage local care markets. The vast majority of care workers are employed by private sector providers which set their terms and conditions, including renumeration for travel costs, independently of Government. Local authorities work with care providers to determine fee rates, which should take account of employment costs, based on local market conditions.<\/p><p>We are committing £1.36 billion to the Market Sustainability and Fair Cost of Care Fund. The Fund will support local authorities to prepare markets for reform and move towards paying providers a fair cost of care. The Government continues to work with local government and care providers to understand the impact from challenges such as energy price rises and inflationary pressures.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4679", "label" : {"_value" : "Biography information for Neil O'Brien"}
        }
        , "answeringMemberConstituency" : {"_value" : "Harborough"}
        , "answeringMemberPrinted" : {"_value" : "Neil O'Brien"}
        , "dateOfAnswer" : {"_value" : "2022-09-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504900/answer/previousversion/17725", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-20T14:35:49.907Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Care Workers: Allowances"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if his Department will offer support to local authorities to help social care providers to increase the mileage allowance paid to care workers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4811", "label" : {"_value" : "Biography information for Navendu Mishra"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stockport"}
      , "tablingMemberPrinted" : [{"_value" : "Navendu Mishra"}
      ], "uin" : "47691"}
    , {"_about" : "http://data.parliament.uk/resources/1504906", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504906/answer", "answerText" : {"_value" : "<p>As part of this years\u2019 World Sickle Cell Day, NHS England launched a new sickle cell disease awareness campaign on the signs and symptoms of sickle cell disease, aimed at urgent and emergency care staff and those living with the condition and their carers.<\/p><p>There have been recent improvements to the haematology medical curriculum, with understanding sickle cell disease and thalassemia now described in the curriculum as core competencies. Health Education England (HEE) provides e-learning which includes content on sickle cell disease. HEE has held discussions with the Royal Colleges of Pathology and Physicians to ensure this curriculum is deliverable to all four nations, in line with General Medical Council\u2019s (GMC) standards. The Haemoglobinopathy Coordinating Centres also provide network development, leadership, learning and education.<\/p><p>The Sickle Cell Society and the All-Party Parliamentary Group on Sickle Cell and Thalassaemia report \u2018No One\u2019s Listening\u2019 highlighted the lack of awareness of sickle cell disease among healthcare professionals. Officials are considering the report\u2019s recommendations. NHS England estimates that awareness amongst accident and emergency medical and nursing staff, specifically of conditions such as sickle cell disease, is high across England and in areas where there is a higher prevalence of the condition. However, NHS England and other bodies continue with further awareness raising.<\/p><p>No specific assessment has been made regarding the extent of compliance to the National Institute for Health and Care Excellence\u2019s (NICE) guidance on pain relief for sickle cell patients. The Care Quality Commission (CQC) considers evidence of how registered persons have met fundamental standards through its regulatory approach. The CQC will consider the processes providers have to ensure that best practice is implemented for quality standards, including NICE\u2019s guidelines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2022-09-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "47332"}
        , {"_value" : "47333"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504906/answer/previousversion/17713", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-20T14:27:53.187Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sickle Cell Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to (a) increase awareness of Sickle Cell disease and (b) improve the training for dealing with that disease among (i) nurses and doctors in training and (ii) practising NHS nurses and doctors.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/163", "label" : {"_value" : "Biography information for Sir Stephen Timms"}
      }
      , "tablingMemberConstituency" : {"_value" : "East Ham"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Stephen Timms"}
      ], "uin" : "47331"}
    , {"_about" : "http://data.parliament.uk/resources/1504908", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504908/answer", "answerText" : {"_value" : "<p>As part of this years\u2019 World Sickle Cell Day, NHS England launched a new sickle cell disease awareness campaign on the signs and symptoms of sickle cell disease, aimed at urgent and emergency care staff and those living with the condition and their carers.<\/p><p>There have been recent improvements to the haematology medical curriculum, with understanding sickle cell disease and thalassemia now described in the curriculum as core competencies. Health Education England (HEE) provides e-learning which includes content on sickle cell disease. HEE has held discussions with the Royal Colleges of Pathology and Physicians to ensure this curriculum is deliverable to all four nations, in line with General Medical Council\u2019s (GMC) standards. The Haemoglobinopathy Coordinating Centres also provide network development, leadership, learning and education.<\/p><p>The Sickle Cell Society and the All-Party Parliamentary Group on Sickle Cell and Thalassaemia report \u2018No One\u2019s Listening\u2019 highlighted the lack of awareness of sickle cell disease among healthcare professionals. Officials are considering the report\u2019s recommendations. NHS England estimates that awareness amongst accident and emergency medical and nursing staff, specifically of conditions such as sickle cell disease, is high across England and in areas where there is a higher prevalence of the condition. However, NHS England and other bodies continue with further awareness raising.<\/p><p>No specific assessment has been made regarding the extent of compliance to the National Institute for Health and Care Excellence\u2019s (NICE) guidance on pain relief for sickle cell patients. The Care Quality Commission (CQC) considers evidence of how registered persons have met fundamental standards through its regulatory approach. The CQC will consider the processes providers have to ensure that best practice is implemented for quality standards, including NICE\u2019s guidelines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2022-09-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "47331"}
        , {"_value" : "47333"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504908/answer/previousversion/17714", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-20T14:27:53.24Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sickle Cell Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the level of awareness among NHS ambulance and A and E staff of the need for urgency in dealing with a Sickle Cell crisis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/163", "label" : {"_value" : "Biography information for Sir Stephen Timms"}
      }
      , "tablingMemberConstituency" : {"_value" : "East Ham"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Stephen Timms"}
      ], "uin" : "47332"}
    , {"_about" : "http://data.parliament.uk/resources/1504909", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1504909/answer", "answerText" : {"_value" : "<p>As part of this years\u2019 World Sickle Cell Day, NHS England launched a new sickle cell disease awareness campaign on the signs and symptoms of sickle cell disease, aimed at urgent and emergency care staff and those living with the condition and their carers.<\/p><p>There have been recent improvements to the haematology medical curriculum, with understanding sickle cell disease and thalassemia now described in the curriculum as core competencies. Health Education England (HEE) provides e-learning which includes content on sickle cell disease. HEE has held discussions with the Royal Colleges of Pathology and Physicians to ensure this curriculum is deliverable to all four nations, in line with General Medical Council\u2019s (GMC) standards. The Haemoglobinopathy Coordinating Centres also provide network development, leadership, learning and education.<\/p><p>The Sickle Cell Society and the All-Party Parliamentary Group on Sickle Cell and Thalassaemia report \u2018No One\u2019s Listening\u2019 highlighted the lack of awareness of sickle cell disease among healthcare professionals. Officials are considering the report\u2019s recommendations. NHS England estimates that awareness amongst accident and emergency medical and nursing staff, specifically of conditions such as sickle cell disease, is high across England and in areas where there is a higher prevalence of the condition. However, NHS England and other bodies continue with further awareness raising.<\/p><p>No specific assessment has been made regarding the extent of compliance to the National Institute for Health and Care Excellence\u2019s (NICE) guidance on pain relief for sickle cell patients. The Care Quality Commission (CQC) considers evidence of how registered persons have met fundamental standards through its regulatory approach. The CQC will consider the processes providers have to ensure that best practice is implemented for quality standards, including NICE\u2019s guidelines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2022-09-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "47331"}
        , {"_value" : "47332"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1504909/answer/previousversion/17715", "answeringMember" : "http://data.parliament.uk/members/4098", "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"}
          , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"}
        }
        , "questionFirstAnswered" : [{"_value" : "2022-09-20T14:27:53.29Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sickle Cell Diseases: Analgesics"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the extent of compliance in the NHS with NICE guidance that Sickle Cell patients should receive pain relief within 30 minutes of admittance to Accident and Emergency care; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/163", "label" : {"_value" : "Biography information for Sir Stephen Timms"}
      }
      , "tablingMemberConstituency" : {"_value" : "East Ham"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Stephen Timms"}
      ], "uin" : "47333"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.previousAnswerVersion.answeringMemberPrinted=Dr+Th%C3%A9r%C3%A8se+Coffey&min-answer.dateOfAnswer=2017-11-17&_page=1", "page" : 0, "startIndex" : 1, "totalResults" : 23, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}